AU2012212142B2 - Methods of using ALK inhibitors - Google Patents

Methods of using ALK inhibitors Download PDF

Info

Publication number
AU2012212142B2
AU2012212142B2 AU2012212142A AU2012212142A AU2012212142B2 AU 2012212142 B2 AU2012212142 B2 AU 2012212142B2 AU 2012212142 A AU2012212142 A AU 2012212142A AU 2012212142 A AU2012212142 A AU 2012212142A AU 2012212142 B2 AU2012212142 B2 AU 2012212142B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
formula
alk
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012212142A
Other languages
English (en)
Other versions
AU2012212142A1 (en
Inventor
Jennifer L. Harris
Nanxin LI
Peter McNAMARA
Fangxian SUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012212142(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012212142A1 publication Critical patent/AU2012212142A1/en
Application granted granted Critical
Publication of AU2012212142B2 publication Critical patent/AU2012212142B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: IRM LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012212142A 2011-02-02 2012-02-02 Methods of using ALK inhibitors Active AU2012212142B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
US61/438,878 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (2)

Publication Number Publication Date
AU2012212142A1 AU2012212142A1 (en) 2013-08-15
AU2012212142B2 true AU2012212142B2 (en) 2015-09-24

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012212142A Active AU2012212142B2 (en) 2011-02-02 2012-02-02 Methods of using ALK inhibitors

Country Status (22)

Country Link
US (1) US8703787B2 (enExample)
EP (1) EP2670401B1 (enExample)
JP (1) JP5837095B2 (enExample)
KR (1) KR101521861B1 (enExample)
CN (1) CN103458881B (enExample)
AU (1) AU2012212142B2 (enExample)
BR (1) BR112013019643B1 (enExample)
CA (1) CA2824092C (enExample)
CY (1) CY1116662T1 (enExample)
DK (1) DK2670401T3 (enExample)
EA (1) EA023404B1 (enExample)
ES (1) ES2543567T3 (enExample)
HR (1) HRP20150946T1 (enExample)
HU (1) HUE025395T2 (enExample)
ME (1) ME02200B (enExample)
MX (1) MX2013008791A (enExample)
PL (1) PL2670401T3 (enExample)
PT (1) PT2670401E (enExample)
RS (1) RS54189B1 (enExample)
SI (1) SI2670401T1 (enExample)
SM (1) SMT201500300B (enExample)
WO (1) WO2012106540A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
IN2015DN04175A (enExample) * 2012-11-07 2015-10-16 Novartis Ag
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
WO2015003658A1 (en) * 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
KR101733733B1 (ko) * 2014-06-17 2017-05-11 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN109715620B (zh) * 2016-08-29 2022-05-06 密歇根大学董事会 作为alk抑制剂的氨基嘧啶
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ES2444222T3 (es) 2006-07-10 2014-02-24 Goji Limited Preparación de alimentos
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neoplasia, January 2011, vol. 13, no. 1, pp. 1-11 *

Also Published As

Publication number Publication date
HUE025395T2 (en) 2016-02-29
PT2670401E (pt) 2015-10-12
EA201391114A1 (ru) 2013-12-30
CN103458881B (zh) 2015-08-12
SMT201500300B (it) 2016-01-08
CA2824092C (en) 2020-06-30
MX2013008791A (es) 2013-10-07
DK2670401T3 (en) 2015-09-07
KR20130121174A (ko) 2013-11-05
WO2012106540A1 (en) 2012-08-09
EP2670401B1 (en) 2015-06-10
SI2670401T1 (sl) 2015-10-30
PL2670401T3 (pl) 2015-11-30
EP2670401A1 (en) 2013-12-11
BR112013019643B1 (pt) 2022-04-19
ES2543567T3 (es) 2015-08-20
US20130296357A1 (en) 2013-11-07
EA023404B1 (ru) 2016-05-31
CY1116662T1 (el) 2017-03-15
AU2012212142A1 (en) 2013-08-15
KR101521861B1 (ko) 2015-05-21
US8703787B2 (en) 2014-04-22
CN103458881A (zh) 2013-12-18
HRP20150946T1 (hr) 2015-10-09
BR112013019643A2 (pt) 2016-10-04
JP2014504646A (ja) 2014-02-24
CA2824092A1 (en) 2012-08-09
JP5837095B2 (ja) 2015-12-24
ME02200B (me) 2016-02-20
RS54189B1 (sr) 2015-12-31

Similar Documents

Publication Publication Date Title
AU2012212142B2 (en) Methods of using ALK inhibitors
AU2019314624B2 (en) Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
AU2008273426B2 (en) Di(arylamino)aryl compounds
US7109219B2 (en) Nitrogen-containing aromatic derivatives
US8785459B2 (en) Quinazoline compounds as kinase inhibitors
CN101137382A (zh) 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
TW201733580A (zh) Ｔｒｋ抑制劑抵抗性的癌治療劑
JP6708849B1 (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
KR20190110581A (ko) 암 치료
KR20230154793A (ko) 암 치료를 위한 병용 요법
AU2019241625A1 (en) Therapeutic agent for hepatocellular carcinoma
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
KR20210126654A (ko) 암 치료
CN106456636A (zh) 包含吡嗪甲酰胺化合物作为活性成分的药物组合物
EP2177222B1 (en) Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
CN109789130A (zh) Bcl-2抑制剂与mcl-1抑制剂的组合、其用途和药物组合物
CN103638028A (zh) 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
WO2017090699A1 (ja) ピラジンカルボキサミド化合物を有効成分とするがん免疫治療用医薬組成物、及び／又は、免疫活性化用医薬組成物
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
HK40007956A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): IRM LLC

FGA Letters patent sealed or granted (standard patent)